Maximum quantity allowed is 999
请选择数量
CAS RN: 38821-49-7 | 产品编码: C2450
Carbidopa Monohydrate
×
![]()
×
技术规格
| Appearance | White to Light yellow powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 %(calcd.on dried substance) |
| Specific rotation [a]20/D | -21.0 ～ -23.5 deg(C=1, AlCl3 sol.) |
| Drying loss | 5.9 to 8.8 % |
物性（参考值）
| 比旋光度 [α]D | -22° (C=1,AlCl3 sol.) |
GHS
相关法规
| RTECS# | MW5300000 |
运输信息
| HS编码* | 2928.00-000 |
应用
Carbidopa: A Competitive Inhibitor of Aromatic L-Amino Acid Decarboxylase
Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase. Carbidopa is often used with L-DOPA [D0600] for the treatment of Parkinson's disease. L-DOPA, the metabolic precursor of dopamine [A0305], does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. However, when L-DOPA is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues. Administration of dopamine alone is ineffective in the treatment of Parkinson's disease apparently because dopamine does not cross the blood-brain barrier. Carbidopa inhibits decarboxylation of L-DOPA. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more L-DOPA available for transport to the brain. Carbidopa does not cross the blood-brain barrier and does not affect the metabolism of L-DOPA within the central nervous system. (The product is for research purpose only.)
References
- L-Dopa Therapy Combined with Peripheral Decarboxylase Inhibitor (MK-486) in Parkinsonism
- Metabolism of Carbidopa [L-(-)-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic Acid Monohydrate], an Aromatic Amino Acid Decarboxylase Inhibitor, in the Rat, Dog, Rhesus Monkey, and Man
- Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism
- Treatment of Parkinson's disease in the advanced stage (a review)
- Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography-electrochemical detection using an online flow injection analysis sample pretreatment unit
- Quantitative analysis of levodopa, carbidopa and methyldopa in human plasma samples using HPLC-DAD combined with second-order calibration based on alternating trilinear decomposition algorithm
参考文献
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。